India finally agrees to trials

Article Abstract:

A clinical trial using three or possibly four vaccines against leprosy will take place in India. There has been a dispute going on for nearly four years, as to which vaccine should be used in India. The World Health Organisation (WHO) has developed a vaccine using heat-killed Mycobacterium leprae, the bacteria that causes leprosy, grown in the armadillo. Clinical trials using this vaccine have already taken place in Malawi and Venezuela. Scientists studying leprosy have argued that there is no need for the WHO vaccine as there are already effective vaccines available which are produced in India. The expense of the WHO vaccine, the necessity to import it, the need for multiple injections and the fact that the WHO vaccine is not safe for children under the age of 12 are arguments against its use. After the clinical trial in India and a comparison to several Indian vaccines, the one which provides the best protection against leprosy will be used.

Research, Prevention, Vaccines, World Health Organization, Leprosy

---

India moves ahead cautiously on US AIDS project

Article Abstract:

The US National Institute for Health (NIH) has spent $3 million for a project in Pune to prepare for an AIDS/HIV Vaccine Evaluation (PAVE) scheme. It is a joint project between the National AIDS Research Institute (NARI) of the Indian Council of Medical Research (ICMR) and researcher Robert Bollinger of Johns Hopkins University in Baltimore, Maryland. The Indian government has stated that the preventive AIDS vaccine trials would not take place until it has been tested in its country of origin. The $100 million loan to control the problem of AIDS in India, taken almost entirely from the World Bank, will be spent to create awareness through advertising, for better equipment in hospitals and for the promotion of condoms.

Achievements and awards, United States. National Institutes of Health, AIDS (Disease)

---

Johns Hopkins embroiled in fresh misconduct allegations

Article Abstract:

Issues concerning accusations of misconduct by a researcher from Johns Hopkins University, Baltimore are discussed. In particular the unethical use of a cancer drug in a clinical trial carried out in Kerala, India is examined.

Drugs, Clinical trials, Ethical aspects, Johns Hopkins University

Similar abstracts:

• Abstracts: Auxin regulates SCFTIR1-dependent degradation of AUX/IAA proteins. Transporters on the move
• Abstracts: Landscape ecology approaches to wetland species conservation: a case study of two turtle species in Southern Maine
• Abstracts: Indians within conservation units: lessons from the Atlantic forest. Inherent rarity in community restoration
• Abstracts: Reversal in the direction of movement of a molecular motor. A step dissected. Switching on kinesin
• Abstracts: Smithsonian heeds physicists' complaints. US physicists rally to save standards agency. Physicists rally behind linear-collider plan

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.